Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Recombinant Human Prolactin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Subjects will meet the following criteria:~1. 18 to 40 years of age~2. Normal weight (BMI 17 to £ 30 kg/m2)~3. Good general health~4. On no medications for at least 3 months before the study~5. Regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase progesterone level~6. No evidence of androgen excess~7. Normal TSH, prolactin and hematocrit~8. No current interest in conception~9. No history of osteoporosis~10. No use of medications known to affect bone turnover~11. No alcoholism~12. No smoking~13. No history of medical problems or treatment known to affect bone turnover.~Exclusion Criteria:~Subjects will be excluded for pregnancy or evidence of breast masses.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- recombinant human prolactin (Type: EXPERIMENTAL): Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline placebo subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).